Treatment results
| . | All, n . | CI,* % (SE) . | Risk group . | |||||
|---|---|---|---|---|---|---|---|---|
| SR, n . | CI,* % (SE) . | MR, n . | CI,* % (SE) . | HR, n . | CI,* % (SE) . | |||
| Overall | 2169 | 758 | 1157 | 254 | ||||
| Death before CR | 16‖ | 0.7 (0.2) | 0 | 13 | 1.1 (0.3) | 3 | 1.2 (0.7) | |
| Resistant disease | 4 | 0.2 (0.1) | 0 | 0 | 4 | 1.6 (0.8) | ||
| Death in first CR | 46 | 2.1 (0.3) | 5 | 0.7 (0.3) | 19 | 1.6 (0.4) | 22 | 8.7 (2.1) |
| During/after chemotherapy | 33¶ | 0.6 (0.2) | 5 | 0.7 (0.3) | 19 | 1.6 (0.4) | 9 | 3.5 (1.2) |
| After stem cell transplantation† | 13 | 1.5 (0.3) | 0 | 0 | 13 | 5.1 (1.8) | ||
| Relapses | 356 | 16.2 (0.8) | 62 | 7.8 (1.0) | 197 | 16.8 (1.2) | 97 | 38.6 (3.6) |
| Isolated BM | 232 | 10.5 (0.7) | 41 | 5.1 (0.8) | 120 | 10.1 (1.0) | 71 | 28.3 (3.6) |
| Isolated CNS | 39 | 1.8 (0.3) | 8 | 1.1 (0.4) | 25 | 2.2 (0.5) | 6 | 2.4 (1.2) |
| Isolated testes | 12 | 0.5 (0.2) | 3 | 0.4 (0.3) | 8 | 0.6 (0.3) | 1 | 0.4 (0.7) |
| Combined CNS/BM involved | 48 | 2.2 (0.4) | 6 | 0.8 (0.3) | 31 | 2.7 (0.5) | 11 | 4.3 (1.7) |
| Combined BM/other (without CNS) | 22 | 1.0 (0.2) | 3 | 0.3 (0.2) | 13 | 1.2 (0.4) | 6 | 2.4 (1.5) |
| Other relapses‡ | 3 | 0.1 (0.1) | 1 | 0.1 (0.1) | 0 | 2 | 0.8 (0.9) | |
| Secondary neoplasms§ | 30 | 2.0 (0.4) | 17 | 2.4 (0.6) | 11 | 1.8 (0.7) | 2 | 2.1 (1.5) |
| . | All, n . | CI,* % (SE) . | Risk group . | |||||
|---|---|---|---|---|---|---|---|---|
| SR, n . | CI,* % (SE) . | MR, n . | CI,* % (SE) . | HR, n . | CI,* % (SE) . | |||
| Overall | 2169 | 758 | 1157 | 254 | ||||
| Death before CR | 16‖ | 0.7 (0.2) | 0 | 13 | 1.1 (0.3) | 3 | 1.2 (0.7) | |
| Resistant disease | 4 | 0.2 (0.1) | 0 | 0 | 4 | 1.6 (0.8) | ||
| Death in first CR | 46 | 2.1 (0.3) | 5 | 0.7 (0.3) | 19 | 1.6 (0.4) | 22 | 8.7 (2.1) |
| During/after chemotherapy | 33¶ | 0.6 (0.2) | 5 | 0.7 (0.3) | 19 | 1.6 (0.4) | 9 | 3.5 (1.2) |
| After stem cell transplantation† | 13 | 1.5 (0.3) | 0 | 0 | 13 | 5.1 (1.8) | ||
| Relapses | 356 | 16.2 (0.8) | 62 | 7.8 (1.0) | 197 | 16.8 (1.2) | 97 | 38.6 (3.6) |
| Isolated BM | 232 | 10.5 (0.7) | 41 | 5.1 (0.8) | 120 | 10.1 (1.0) | 71 | 28.3 (3.6) |
| Isolated CNS | 39 | 1.8 (0.3) | 8 | 1.1 (0.4) | 25 | 2.2 (0.5) | 6 | 2.4 (1.2) |
| Isolated testes | 12 | 0.5 (0.2) | 3 | 0.4 (0.3) | 8 | 0.6 (0.3) | 1 | 0.4 (0.7) |
| Combined CNS/BM involved | 48 | 2.2 (0.4) | 6 | 0.8 (0.3) | 31 | 2.7 (0.5) | 11 | 4.3 (1.7) |
| Combined BM/other (without CNS) | 22 | 1.0 (0.2) | 3 | 0.3 (0.2) | 13 | 1.2 (0.4) | 6 | 2.4 (1.5) |
| Other relapses‡ | 3 | 0.1 (0.1) | 1 | 0.1 (0.1) | 0 | 2 | 0.8 (0.9) | |
| Secondary neoplasms§ | 30 | 2.0 (0.4) | 17 | 2.4 (0.6) | 11 | 1.8 (0.7) | 2 | 2.1 (1.5) |
CR indicates complete remission; BM, bone marrow; CNS, central nervous system; SR, standard risk; MR, medium risk; HR, high risk.
Cumulative incidences are indicated at 6 years except for the secondary neoplasms, which are calculated at 10 years.
A total of 58 patients underwent allogeneic stem cell transplantation in first CR.
Numbers of isolated mediastinal cases (1); isolated lumbosacral epidural (1); relapse site unknown (1; relapse diagnosed abroad).
Four additional secondary neoplasms developed after relapse and relapse treatment.
Numbers of leukemia-associated cases: hypoxia resulting from mediastinal mass (1); cerebral bleeding (2); bacterial sepsis (1); multiple organ failure resulting from tumor lysis syndrome (1); treatment-related: bacterial sepsis (6); cerebral bleeding (1); cerebral thrombosis (2); multiple organ failure (1); disseminated intravascular coagulation (1).
Number of cases of bacterial sepsis (8); fungal infection (9); viral infection (1); pneumocystis carinii pneumonia (1); infection/sepsis with unknown pathogen (7); progressive leukencephalopathy (1); cerebral bleeding (2); cerebral infarction (1); interstitial pneumonia of unknown origin (2); and erroneous intrathecal vincristine application (1).